Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of P03277 (Elucirem) in Healthy Volunteers and Patients with Renal Impairment
NCT03657784Phase 1Completed
- Sponsor
- Guerbet
- Start
- Oct 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of gadopiclenol (5 arms), sponsored by Guerbet. Primary endpoints: Area Under the Curve at 96 hours, Maximum Plasma Concentration at 96 hours and 6 more. Started Oct 2017; status: completed.
02
Drugs
gadopiclenol
Beyond the preview
Go deeper on NCT03657784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657784.